Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of G3215 in Adult Subjects
NCT02692040Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Jan 2015
- Primary completion
- Jan 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of G3215 in type 2 diabetes mellitus (T2DM), obesity and prediabetes (19 arms), sponsored by Imperial College London. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Jan 2015; status: completed.
02
Drugs
G3215
03
Conditions
type 2 diabetes mellitus (T2DM)obesityprediabetes
Beyond the preview
Go deeper on NCT02692040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02692040.